Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Net Income	-538.64	-205.28	-176.06	-140.85	-84.55	67.98
Depreciation & Amortization	17.43	12.49	10.42	8.27	5.94	4.44
Loss (Gain) From Sale of Investments	-0.08	-	4.43	-1.71	-0.02	-
Stock-Based Compensation	72.68	78.13	120.89	76.67	43.38	12.39
Other Operating Activities	21.14	12.31	2.48	0.27	0.53	1.07
Change in Accounts Receivable	1.25	1.41	8.85	-9.41	-0.18	-0.33
Change in Accounts Payable	30.78	33	-6.59	2.63	-0.82	4.84
Change in Unearned Revenue	-16.91	-129.18	-112.5	223.26	-63.51	82.8
Change in Other Net Operating Assets	60.79	43.23	11.95	12.19	3.44	-0.16
Operating Cash Flow	-351.56	-153.89	-136.13	171.31	-95.8	173.04
Capital Expenditures	-181.09	-176.74	-52.78	-23.57	-11.95	-12
Investment in Securities	14.45	80.58	47.36	-118.11	-228.83	-35.75
Investing Cash Flow	-166.64	-96.16	-5.42	-141.68	-240.78	-47.75
Long-Term Debt Repaid	-	-	-	-	-	-2.42
Net Debt Issued (Repaid)	-	-	-	-	-	-2.42
Issuance of Common Stock	432.25	3.05	5.19	11.31	257.95	68.8
Other Financing Activities	50	250	60	-	-	-
Financing Cash Flow	482.25	253.05	65.19	11.31	257.95	66.38
Foreign Exchange Rate Adjustments	0.01	-0.12	-0.07	-0.09	0.41	-
Net Cash Flow	-35.94	2.89	-76.43	40.85	-78.22	191.67
Free Cash Flow	-532.65	-330.63	-188.91	147.75	-107.75	161.03
Free Cash Flow Margin	-2710.95%	-137.34%	-77.67%	106.84%	-122.46%	95.40%
Free Cash Flow Per Share	-4.61	-3.10	-1.79	1.42	-1.07	1.63
Cash Interest Paid	-	-	-	-	-	0.03
Cash Income Tax Paid	3.06	-	0	0	-0.1	0.3
Levered Free Cash Flow	-413.91	-254.47	-60.64	63	-78.67	123.7
Unlevered Free Cash Flow	-399.56	-243.01	-60.64	63	-78.67	123.7
Change in Net Working Capital	-33.43	28.77	27.61	-94.77	57.82	-80.62

Source: S&P Capital IQ. Standard template. Financial Sources.